Table 4.
Among subcohort only, association of change in cardiac biomarkers with all-cause mortality (n = 842)
| Cardiac biomarker | N at risk | N events | Unadjusted |
Model 1 |
Model 2 |
|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | |||
| Absolute change | |||||
| NT-proBNP (pg/ml) | |||||
| ≤ −14.3 | 211 | 56 | 0.33 (0.22, 0.49) | 0.55 (0.36, 0.86) | 0.55 (0.36, 0.86) |
| −14.2 to 285 | 420 | 42 | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| > 285 | 211 | 64 | 1.17 (0.82, 1.68) | 1.31 (0.89, 1.94) | 1.24 (0.84, 1.84) |
| hsTnT (ng/ml) | |||||
| ≤ −0.247 | 211 | 37 | 0.83 (0.55, 1.24) | 0.95 (0.63, 1.45) | 0.99 (0.65, 1.50) |
| −0.246 to 11.1 | 420 | 65 | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| >11.1 | 211 | 60 | 1.67 (1.11, 2.52) | 1.31 (0.85, 2.02) | 1.33 (0.86, 2.06) |
| GDF-15 (pg/ml) | |||||
| ≤ −122 | 211 | 39 | 0.76 (0.51, 1.13) | 1.25 (0.79, 1.97) | 1.28 (0.81, 2.03) |
| −121 to 585 | 421 | 63 | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| >585 | 210 | 60 | 1.64 (1.09, 2.45) | 1.50 (0.93, 2.42) | 1.54 (0.95, 2.48) |
| sST-2 (ng/ml) | |||||
| ≤ −3.91 | 211 | 56 | 0.49 (0.34, 0.71) | 0.67 (0.44, 1.01) | 0.60 (0.40, 0.92) |
| −3.9 to 3.46 | 420 | 60 | 1.0 (Ref.) | 1.0 (Ref.) | 1.0 (Ref.) |
| >3.46 | 211 | 46 | 0.78 (0.53, 1.15) | 0.88 (0.57, 1.38) | 0.88 (0.56, 1.37) |
CI, confidence interval; GDF-15, growth differentiation factor−15; HR, hazard ratio; hsTnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sST-2, soluble ST-2.
Model 1: age, sex, race/ethnicity, site, diabetes, cardiovascular disease, body mass index, smoking, systolic blood pressure, low-density lipoprotein, high-density lipoprotein, estimated glomerular filtration rate, log-transformed urine protein, and baseline level of biomarker. Model 2: Model 1 + fibroblast growth factor−23, phosphorus, beta blockers, ACEi/ARBs, diuretics.